Sanofi

FDA approves generic Taxotere

Friday, March 11, 2011 01:47 PM

Hospira has won approval for the first U.S. generic version of Sanofi-aventis’ Taxotere cancer drug, according to a Reuters report.

More... »

Genzyme sells pharmaceuticals segment

Monday, March 7, 2011 10:49 AM

Cambridge, Mass.-based Genzyme has completed the sale of its pharmaceutical intermediates business to Germany's International Chemical Investors Group for an undisclosed amount, according to BIOSmartBrief.

More... »

AstraZeneca joins quest for TB therapies

Monday, March 7, 2011 10:43 AM

AstraZeneca became the newest member of a $22 million multi-member partnership to find new therapies for tuberculosis. The current remedies for the disease have been in use for over 50 years, and require several months or years of treatment. But with the expertise and help of companies including AZ and Sanofi-aventis, and academic partners University of Cambridge and institutions in Pavia, Italy and Uppsala, Sweden, the group hopes to cut treatment time.

More... »

Two CROs honored for employee training programs

Thursday, March 3, 2011 06:16 AM

Two global contract research organizations—Quintiles Transnational and Kendle—have been named to the Training Top 125 list, which recognizes excellence in employer-sponsored training and development programs.

More... »

FDA issues warning letter to Sanofi-aventis

Tuesday, March 1, 2011 08:00 AM

The FDA has warned Sanofi-Aventis’ U.S. unit for failing to submit reports of possible serious drug side effects in a timely manner. In a Jan. 28 letter made public last week, the FDA said an early response from the drugmaker and its "promised corrective actions are inadequate to address the deficiencies."

More... »

Sanofi’s $20 billion Genzyme buy could fuel a big pharma-biotechnology acquisition trend

Tuesday, February 22, 2011 10:06 AM

Could last Wednesday’s $20 billion Sanofi-aventis acquisition of Genzyme signal the beginning of an industry trend in which big pharmaceutical companies stop buying each other and start buying robust biotechnology firms?

More... »

New $1b NIH center will tackle early-stage drug development to ease industry risk of failure

Monday, February 7, 2011 07:00 AM

A billion-dollar U.S. government drug development center, which will focus on moving potential new discoveries out of the lab and into early-phase trials, could help biopharmaceutical companies improve their success rate in developing new treatments by reducing the risk of failure in early-stage research.

More... »

More big pharmaceuticals join trend of partnering with CROs to cut costs, speed drug development

Monday, October 11, 2010 10:27 AM

Major pharmaceutical companies are increasingly forming long-term, strategic partnerships with a small number of global contract research organizations (CROs) in order to cut costs and streamline their outsourced clinical work.

More... »

Covance and Sanofi-aventis ink landmark 10-year, $2.2 billion R&D outsourcing partnership

Monday, October 4, 2010 10:01 AM

Hailed as the largest outsourcing partnership between a contract research organization (CRO) and a pharmaceutical company, Covance and Sanofi-aventis have signed a 10-year agreement in which the CRO will provide France’s largest pharmaceutical company with a wide range of research and drug development services, and receive between $1.2 billion and $2.2 billion in revenue.

More... »

Covance and Sanofi-Aventis sign 10-year, $2.2 billion strategic R&D alliance

Thursday, September 30, 2010 09:52 AM

CRO Covance, based in Princeton, N.J., today announced the signing of definitive agreements with Sanofi-aventis for a research and development partnership worth up to $2.2 billion.

More... »